

Figure S1. Spectral properties of the bromocryptine (BEC)- and midazolam-bound CYP3A4 (panels A-B and C-D, respectively). A and C - Spectral changes observed during equilibrium titrations of ligand-free CYP3A4 with bromocryptine and midazolam, respectively. B and D-Spectral changes observed during equilibrium titrations of bromocryptine- and midazolam-bound CYP3A4, respectively, with ritonavir. In panels A and C, absorbance spectra of ligand-free and substrate-bound CYP3A4 recorded at the end of titration are in black and red, respectively. In panels B and D, spectra of the CYP3A4-ritonavir complex are in light-brown. In competitive displacement experiments, the bromocryptine and midazolam concentrations were $10 \mu \mathrm{M}$ and $280 \mu \mathrm{M}$, respectively. In all panels, left insets are the difference spectra recorded in a separate experiment where equal amounts of dimethyl sulfoxide (DMSO) were added to the reference cuvette to correct for the solvent-induced spectral perturbations. Right insets are titration plots derived from the difference spectra with hyperbolic or quadratic fittings. Spectral dissociation constants $\left(\mathrm{K}_{\mathrm{s}}\right)$ are indicated.
A
B




Figure S2. A-C, Simulated annealing omit electron density maps for mibefradil, azamulin and $6^{\prime}, 7^{\prime}-$ dihydroxybergamottin ( $6009,600 \mathrm{~A}$ and 600 B structures, respectively) shown as green mesh and contoured at $3 \sigma$ level. In panel C, cyan sphere is a water molecule ligated to the heme iron.


Figure S3. A and B, Structural superposition of ligand-free CYP3A4 (in black; 5VCC model) and its complexes with mibefradil and $6^{\prime}, 7^{\prime}$-dihydroxybergamottin (60O9 and 60OB structures, respectively). Virtually no structural rearrangement was induced upon association of both substrates (shown in space-filling representation). Root-mean-square deviation between the $\mathrm{C} \alpha$-atoms of the superimposed structures was $<0.45 \AA$.


Figure S4. Superposition of the ligand-free (5VCC; in black) and azamulin-bound CYP3A4 (6OOA; in beige). Residues undergoing conformational rearrangement are displayed and labeled. The F-F' loop, shown in purple in the 5VCC structure, becomes disordered in the CYP3A4-azamulin complex due to steric clashing with the amino-triazolyl end-group. Root-mean-square deviation between the $C \alpha$ atoms of the 5 VCC and 6 OOA structures is $0.63 \AA$. .


Figure S5. A and B, Spectral changes observed during equilibrium titrations of bergamottin- and DHB-bound CYP3A4, respectively, with ritonavir. Spectra of substrate-bound CYP3A4 are in red. Spectra of the CYP3A4-ritonavir complex and its ferrous and ferrous CO-bound forms are in brown, green and blue, respectively. Bergamottin and DHB concentrations were $20 \mu \mathrm{M}$ and $70 \mu \mathrm{M}$, respectively. Left and right insets are the difference spectra and titration plots with quadratic fittings, respectively. The derived spectral dissociation constants for ritonavir ( $\mathrm{K}_{\mathrm{S}}{ }^{\mathrm{RIT}}$ ) were similar and equal to 35 and 32 nM , respectively.

Table S1. Data collection and refinement statistics.

| Ligand dihydroxybergamottin PDB code | mibefradil | azamulin $6^{\prime}, 7^{\prime}-$ |  |
| :---: | :---: | :---: | :---: |
|  | 6009 | 600A | 600B |
| Data collection statistics |  |  |  |
| Space group | I222 | I222 | I222 |
| Unit cell parameters$\AA,$ | $a=78 \AA, b=103 \AA$, | $a=77 \AA, b=102 \AA$, | $a=78 \AA$, $b=102$ |
|  | $\begin{aligned} & c=127 \AA \\ & \alpha, \beta, \gamma=90^{\circ} \end{aligned}$ | $\begin{aligned} & c=126 \AA \AA \\ & \alpha, \beta, \gamma=90^{\circ} \end{aligned}$ | $\begin{aligned} & c=127 \AA ; \\ & \alpha, \beta, \gamma=90^{\circ} \end{aligned}$ |
| Molecules per asymmetric unit | 1 | 1 | 1 |
| Resolution range ( $\AA$ ) | 79.99-2.25 (2.37-2.25) ${ }^{\text {a }}$ | 78.97-2.52 (2.66-2.52) | 79.82-2.20 (2.27- |
| 2.20) |  |  |  |
| Total reflections | 120,774 | 94,344 | 196,832 |
| Unique reflections | 22,832 | 16,915 | 26,105 |
| Redundancy | 5.3 (5.1) | 5.6 (5.6) | 7.5 (5.2) |
| Completeness | 93.4 (93.7) | 100.0 (100.0) | 99.7 (97.6) |
| Average $I / \sigma I$ | 8.7 (0.9) | 11.1 (1.2) | 6.8 (1.0) |
| $\mathrm{R}_{\text {merge }}$ | 0.082 (1.481) | 0.074 (1.502) | 0.102 (0.882) |
| $\mathrm{R}_{\mathrm{pim}}$ | 0.038 (0.691) | 0.034 (0.691) | 0.047 (0.628) |
| CC 1/2 | 0.998 (0.458) | 0.999 (0.366) | 0.998 (0.482) |
| Refinement statistics |  |  |  |
| $R / R_{\text {free }}{ }^{\text {b }}$ | 19.9/26.1 | 19.5/25.2 | 20.7/27.5 |
| No. of protein atoms | 3748 | 3650 | 3689 |
| No. of ligand atoms | 35 | 32 | 26 |
| No. of water molecules | 59 | 15 | 37 |
| Average $B$-factor ( $\AA^{2}$ ): |  |  |  |
| Protein | 92.2 | 103.9 | 97.0 |
| Ligand | 105.4 | 104.4 | 133.9 |
| Ligand fit: |  |  |  |
| RSCC | 0.89 | 0.94 | 0.88 |
| RSR | 0.43 | 0.25 | 0.45 |
| r.m.s. deviations: <br> Bond lengths, $\AA$ | 0.009 | 0.009 | 0.009 |


| Bond angles, ${ }^{\circ}$ | 1.129 | 1.159 | 1.123 |
| :--- | :--- | :--- | :--- |
| Ramachandran plot $^{\mathbf{c}}($ residues; \%) |  |  |  |
| Preferred | $418(93.5 \%)$ | $414(93.9 \%)$ | $418(92 \%)$ |
| Allowed | $29(6.5 \%)$ | $27(6.1 \%)$ | $37(8 \%)$ |
| Outliers | none | none | $1(0.2 \%)$ |

$\overline{{ }^{a}}$ Values in brackets are for the highest resolution shell.
${ }^{\mathbf{b}} R_{\text {free }}$ was calculated from a subset of $5 \%$ of the data that were excluded during refinement. ${ }^{\mathrm{c}}$ Analyzed with PROCHECK.

